7Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase Ⅱ study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy [J]. J Clin Oncol, 2007, 25(16): 2171-2177.
8Reddy BK, Vidyasagar M, Shenoy K, et al. BIOMAb EGFRTM (Nimotuzumab/h-r3) in combination with standard of care in squamous cell carcinoma of head and neck (SCCHN) [J]. Int J Radiat Oncol Biol Phys, 2007, 69(3): S450.
9Crombet T, Osorio M, Cruz T, et al. Use of the humanized anti- epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients [J]. J Clin Oncol, 2004, 22 (9): 1646-1654.
10Spicer J. Technology evaluation: nimotuzumab, the Center of Molecular Immunology/YM BioSciences/Oncoscience [J]. Curr Opin Mol Ther, 2005, 7(2): 182-191.
